Loading
IT
iTeos Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by EcoR1 Capital, LLC, was filed 16 May 2025.
iTeos Therapeutics, Inc.: what insiders have been doing
iTeos Therapeutics, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). Nothing new has been filed by managers of iTeos Therapeutics, Inc. in twelve months, the latest record being from 29 August 2025.
Since 2020, the database holds 19 purchases and 249 sales by insiders of the company.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and EssilorLuxottica. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
465
Thresholds
n/a
Buy Volume
€88M
19 ops. · all time
Sell Volume
€170M
249 ops. · all time
Who traded when
BuySaleMichel Detheux10 sales
David Hallal3 sales
EcoR1 Capital, LLC2 buys
Ansbert Gadicke1 sale
Matthew Gall1 buy
MPM BioVentures 2014, L.P.1 sale
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2024FY ended December 2024 · cache
Income statement
RevenueUS$30.1M
Net income-US$115.7M-384.0% margin
Last declaration on 29 August 2025
Declarations465 total
94,027 sharesCommon StockSEC:0000950170-25-112240:1
161,898 sharesCommon StockSEC:0000950170-25-112241:0
153,903 sharesCommon StockSEC:0000950170-25-112240:0
47,000 sharesCommon StockSEC:0000950170-25-112238:0
89,429 sharesCommon StockSEC:0000950170-25-112236:0
46,300 sharesCommon StockSEC:0000950170-25-112235:0
8,400 shares@ US$10.030.7% of flowCommon StockSEC:0000950170-25-085047:1
43,882 shares@ US$4.301.6% of flowCommon StockSEC:0000950170-25-085047:2
43,882 shares@ US$10.033.7% of flowCommon StockSEC:0000950170-25-085047:3
8,400 shares@ US$4.300.3% of flowCommon StockSEC:0000950170-25-085047:4
8,400 shares@ US$10.020.7% of flowCommon StockSEC:0000950170-25-085047:5
43,883 shares@ US$4.301.6% of flowCommon StockSEC:0000950170-25-085047:6
43,883 shares@ US$10.023.7% of flowCommon StockSEC:0000950170-25-085047:7
18,000 shares@ US$4.300.6% of flowCommon StockSEC:0000950170-25-085047:8
94,027 shares@ US$4.303.4% of flowCommon StockSEC:0000950170-25-085047:9
8,400 shares@ US$4.3050.0% of flowCommon StockSEC:0000950170-25-085047:0
38,227 shares@ US$10.078.0% of flowCommon StockSEC:0000950170-25-083410:1
38,227 shares@ US$4.303.4% of flowCommon StockSEC:0000950170-25-083410:2
38,227 shares@ US$10.158.1% of flowCommon StockSEC:0000950170-25-083410:3
38,228 shares@ US$4.303.4% of flowCommon StockSEC:0000950170-25-083410:4
38,228 shares@ US$10.248.1% of flowCommon StockSEC:0000950170-25-083410:5
8,400 shares@ US$10.100.7% of flowCommon StockSEC:0000950170-25-083411:1
43,883 shares@ US$4.301.6% of flowCommon StockSEC:0000950170-25-083411:2
43,883 shares@ US$10.103.7% of flowCommon StockSEC:0000950170-25-083411:3
8,400 shares@ US$4.300.3% of flowCommon StockSEC:0000950170-25-083411:4
25 of 465 declarations
About iTeos Therapeutics, Inc.
iTeos Therapeutics, Inc. is a U.S.-listed biopharmaceutical company trading on NASDAQ in the United States, focused on immuno-oncology. The company is headquartered in Watertown, Massachusetts, with a research center in Gosselies, Belgium. Its roots go back to a Belgian biotechnology platform founded in 2011, and the current Delaware-incorporated parent, iTeos Therapeutics, Inc., was created in 2019 as the U.S. successor structure. iTeos operates as a clinical-stage oncology company, with a portfolio centered on monoclonal antibodies and small molecules designed to address validated immune pathways, especially in solid tumors.
The company’s lead asset is belrestotug, an anti-TIGIT antibody intended to counter tumor-induced immunosuppression and enhance anti-tumor immune activity. iTeos developed this program in collaboration with GSK under a global collaboration and license agreement that gives GSK commercialization rights outside the United States, while iTeos and GSK share development responsibility and U.S. commercial rights. This partnership has been a key strategic asset for iTeos, providing scientific validation, cost-sharing, and significant milestone potential. The broader pipeline has also included adenosine-pathway programs such as inupadenant (EOS-850), although the company stated in 2024 that the interim data did not justify further investment at that stage.
Read moreShow less
From a competitive standpoint, iTeos operates in one of the most crowded and scientifically demanding areas of oncology drug development. Success depends on clinical differentiation, biomarker strategy, partner quality, and capital efficiency. The company’s main strengths are its translational tumor immunology expertise, its cross-border U.S.-Belgium operating model, and its ability to collaborate with a large pharmaceutical partner. At the same time, the business profile remains typical of a late-stage biotech: concentrated pipeline risk, high R&D intensity, and limited revenue visibility absent product commercialization. The GSK alliance has been central in positioning iTeos as a credible immuno-oncology developer rather than a purely preclinical story.
Geographically, iTeos maintains a transatlantic footprint, with operational capabilities in both the United States and Belgium. A major recent development is the definitive agreement announced in July 2025 for Concentra Biosciences to acquire iTeos for $10.047 in cash per share plus a contingent value right, following a strategic review and board approval. For investors, this means iTeos should be viewed as a biotech asset with notable strategic optionality, but also as a company whose equity story is now closely tied to a transaction outcome rather than only to standalone pipeline execution.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
